Abbott price target raised to $130 from $117 at UBS

UBS raised the firm’s price target on Abbott to $130 from $117 and keeps a Buy rating on the shares. Abbott delivered an "impressive" beat and raise in Q1, which was largely broad-based with Nutrition, EPD, and Medical Devices all driving double-digit organic growth above consensus, the analyst tells investors in a research note. Abbott remains the firm’s top large-cap pick.